GlassScriptPhysician profile
Karishma Patel
NPI 1689126179
$2,290.61
in general payments reported to CMS, 2019-2025
22 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $336 · 2022: $323 · 2023: $844 · 2024: $625 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,631.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $471.37 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $408.17 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $321.12 | 2023-2025 | Cologuard Collection Kit |
| Novocure INC. | $231.94 | 2023-2024 | Optune |
| Biogen, INC. | $166.15 | 2023-2025 | Tysabri, Vumerity |
| Axsome Therapeutics, INC. | $127.38 | 2023-2024 | Sunosi |
| Janssen Pharmaceuticals, INC | $103.19 | 2024 | Invega Sustenna, Invega Trinza |
| Lilly USA, LLC | $57.99 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Amarin Pharma, INC. | $54.83 | 2021 | |
| Genentech USA, INC. | $53.97 | 2021-2024 | Enspryng, Ocrevus |
| Merck Sharp & Dohme LLC | $41.14 | 2021-2023 | Segluromet, Steglatro |
| Abbvie INC. | $32.58 | 2023 | |
| Pfizer INC. | $30.61 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.47 | 2022-2023 | Trulance, Xifaxan |
| Daiichi Sankyo INC. | $28.30 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $27.66 | 2023 | Intracept |
| Abbott Laboratories | $23.65 | 2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $18.91 | 2023 | Gammagard |
| Boston Scientific Corporation | $17.52 | 2023 | Watchman Flx |
| Neurelis, INC. | $15.91 | 2023 | Valtoco |
| Kowa Pharmaceuticals America, INC. | $14.01 | 2022 | |
| Lundbeck LLC | $13.74 | 2024 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karishma Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.